Exemestane PH&T receives Marketing Authorisation in Germany, Greece, Netherlands, Italy, Spain and the United Kingdom.

August 2011 Exemestane PH&T, a third-generation aromatase inhibitor, is an antineoplastic agent.

Exemestane PH&T 25 mg coated tablets, is indicated in the treatment of:

§ adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breast cancer, following 2 – 3 years of initial adjuvant tamoxifen therapy.

§ the treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy. Efficacy has not been demonstrated in patients with oestrogen receptor negative status

Moreover recent Data from the Mammary Prevention (MAP).3 trial, released at the American Society of Clinical Oncology 2011 Annual Meeting, show that Exemestane more than halved the risk for invasive breast cancer (65% reduction).

Exemestane not only presents a new option for chemoprevention, it appears to be safer and more effective than the first class of drugs found to be effective in this setting — the selective estrogen-receptor modulators (SERMs) tamoxifen and raloxifene. Both of these drugs have been proven effective at reducing the risk for breast cancer in women at high risk (tamoxifen by 50%, raloxifene by 38%), but healthy women have been reluctant to take these drugs prophylactically.